DNAstack’s Post

This. Is. Huge. The Target ALS #data portal is live. Access comprehensive datasets from our scientific cores - biofluids, postmortem tissue, and stem cells. No fees. No IP claims. No strings attached. #ALS #research #dataintegration

Dive into insightful sharing from our Future of Omics Conference at Hong Kong station! With a focus on the application of sequencing technologies, we have selected the highlights from the informative keynote speech covering fields of study such as the human microbiome, stem cells, and more. Stay tuned for the upcoming sessions in Shenzhen! #futureofomics #MGIseqALL #seqALL

📢 NEWS: Researchers 🔬 have made an important discovery 🔍 about the internal workings of our cells 🧬, particularly centrosomes and cilia—tiny structures essential for cell division, communication, and movement 🌀. What was once believed to be an empty space within these structures has been revealed to be filled with a network of special proteins, termed microtubule inner proteins (MIPs) 🌌. Scientists 👩🔬👨🔬 from Danish Cancer Institute, Syddansk Universitet - University of Southern Denmark, and University of Cambridge applied advanced computational analyses 💻, structure predictions, and experimental techniques 🧪 to dive deep into the microtubules—the structural skeleton of these cellular components 🌐 They unearthed unique modules within the MIPs, identifying them with names like NWE, SNYG, ELLEn, PYG, and GFG-repeat, based on their distinctive sequences 🔠 The findings, published in the prestigious journal Nature Portfolio 🌟, could have significant implications for the way we use chemotherapy 💊 as treatment. Senior scientist at the DCI Kenneth Schou led the research: 💬 “Several forms of chemotherapy, such as taxanes, work by targeting microtubules. Because microtubules are so widespread in the body not just in cancer cells, the treatment also damages healthy cells, which leads to gross side effects. Therefore, specific targeting of other molecules involved in microtubule-related functions that could lead to the development of treatments are of great interest. For example, by using artificial intelligence-based structural predictions, proteins that bind and regulate microtubules specifically in cancer cells can be predicted and that can pave the way for a next generation of chemotherapy” 💡 #ScienceNews #CellBiology #CancerResearch #NatureCommunications #ArtificialIntelligence

This is really #incredible. Of 142 graduates of our Immersion Science Program at Fox Chase Cancer Center, 36.6% are published authors, contributing new findings to 118 scientific publications since 2013‼ . Over 80% have been paid researchers in college and beyond, 98% graduated from college with STEM degrees, and most importantly, they remain friends and colleagues committed to reducing #healthdisparities in the communities they love. More evidence that #earlycareer #researchexperiences set the stage for #success in #biomedicine. The only way it can get better than this is to make these #opportunities happen for #everyone. #Research4All

✨#Day5; We don’t make noice, we take actions… behind the scenes even! Indeed, the scientific effort to improve accuracy and precision medicine - an effort that currently receives only a minuscule portion of scientific budgets - can arguably save more lives in the next decade than bench science, more lives than research on the genome, stem cell therapy, cancer, vaccines, and all the other laboratory work. This field has the potential to revolutionize healthcare, transforming lives and communities worldwide. From developing targeted therapies to creating personalized treatment plans, biomedical science is pushing the boundaries of human knowledge and innovation. With its unique blend of biology, chemistry, medicine, and technology, it's an ever-evolving landscape of discovery and progress. So, how can you not love biomedical science? 🥹 ✨Laboratory Medicine is my calling and I am not one to miss my call! #BiomedicalScience #LoveScience #medicdiaries #31daystolovebiomedicalscience #MedicalBreakthroughs #HealthcareInnovation #ScienceSavesLives #ResearchMatters #Medicine #Science #Healthcare #MedicalResearch

It’s #FeatureFriday! Today, we’re showing some love for Obatala Sciences! 🌟🧪🔬 Obatala Sciences is an innovative biotech company making waves in the field of clinical research. They’re not just promoting the development of therapies for diseases like obesity, diabetes, and cancer, but also pushing the boundaries in tissue engineering and regenerative medicine. They offer everything from human-derived hydrogels to adult human stem cells from diverse populations, cell culture media, and even tissue chip kits. These products are developed from a pool of human donors representing multiple ethnicities, age groups, and genders. This further embodies their commitment to diversity and representation! Thanks to Obatala Sciences, drug success rates are on the rise, and the time and cost to market are dropping. Here’s to a future where everyone benefits from the advances in healthcare! Learn more on their website: https://lnkd.in/eHhxiQiG #ObatalaSciences #DiversityInScience #HealthcareHeroes

🚀 Exciting M&A News in the Genomics Space! Illumina has officially acquired Fluent BioSciences, a move set to significantly enhance the capabilities of single-cell sequencing and expand the potential for groundbreaking discoveries in genomics. The deal marks a step toward unlocking an even greater customer base. This acquisition underscores Illumina's commitment to innovation and advancing the frontiers of genetic research. Fluent BioSciences brings to the table cutting-edge microfluidic technology that simplifies and scales single-cell RNA sequencing, making it more accessible and cost-effective. With this acquisition, researchers and clinicians can look forward to: - More precise and scalable single-cell sequencing - Accelerated discovery and development in personalized medicine - Expanded applications in cancer research, neurobiology, and beyond As we continue to unlock the mysteries of the human genome, strategic partnerships like this one are critical in driving the next wave of innovations. Kudos to the teams at Illumina and Fluent BioSciences for their dedication to pushing the envelope in genomics! #Genomics #Biotechnology #Microfluidic #Innovation #SingleCellSequencing #PersonalizedMedicine #Illumina #FluentBioSciences #Acquisition #M&A

Congratulations to Dr Megan Mitchell Dr Olivier Loudig from the Center for Discovery and Innovation New Jersey, and to their colleagues, for the recent publication Exhaled breath condensate contains extracellular vesicles (EVs) that carry miRNA cargos of lung tissue origin that can be selectively purified and analyzed. This work presents an innovative approach for isolating EVs from exhaled aerosolized droplets and analyzing their content. By capturing the EVs, the scientists could intercept the "instant bio-messages" that cells use to communicate with one another in the lungs. They used several methods to assess the captured EVs, among them ONI's #EVProfiler kit, depicted in the attached image. This enabled them to not only identify the cells that generated the EVs, but also to carefully characterize the RNA molecules inside the EVs, and study them as diagnostic markers for various diseases, among them lung cancer. Read the full paper here: https://hubs.li/Q02vjXhf0 This paper is a fine example for the potential that EVs hold for the future of biomedical research. There is no doubt that EVs will play a major role in diagnostics and therapeutics, and we are very excited to see what new technologies are coming next. ONI scientists will attend #ISEV2024, where they will present our latest development in EV research, #EVProfiler2 with #AutoEV, as well as #AploFlow, our next generation end-to-end solution for EV capture, analysis and reporting. #Nanoimager #SuperResolution #microscopy #research #ExtraCellularVesicles #Biology #Biophysics #SingleMolecule #SMLM #dSTORM #LifeSciences #diagnostics

Interesting read

📚 Exciting News! Our research paper has been published in the iScience Journal! 🎉 Huge congratulations to Asma Al-Amoodi, the first author of our recently published paper. 📚 Your dedication and contribution have been instrumental. 🔬 Title: α1,3-Fucosylation Treatment Improves Cord blood CD34 Negative HSC Navigation 👥 Authors: Asma Al-Amoodi, Jing Kai, Yanyan Li, Jana S. Malki, Abdullah Alghamdi, Arwa Al-Ghuneim, Alfonso Saera-Vila, Satoshi Habuchi, Jasmeen Merzaban. 📖 Abstract: This groundbreaking study unveils a previously overlooked potential in CD34neg hematopoietic stem cells (HSCs), demonstrating their enhanced homing and engraftment capabilities through α1,3-fucosylation treatment with the Sialyl Lewis X molecule. The findings challenge the long-standing underutilization of CD34negHSCs in diagnostics and suggest a promising avenue for treating blood disorders. Additionally, unique adhesion pathways identified through RNA sequencing emphasize the crucial role of the microenvironment in optimizing CD34neg cell functionality. 🩸🔬 🌐 Read the full article: [https://lnkd.in/eVrddVhH] 🙌 It's been an incredible journey working with this talented team, and I'm proud to be a co-author on this groundbreaking research. Special thanks to everyone involved! 🚀 #Research #Science #Publication #Collaboration